Regeneron aims to stop muscle loss with combination treatment approach in obesity

Re­gen­eron re­it­er­at­ed its plans to jump in­to the weight loss race in 2024, ex­pect­ing to start test­ing a com­bi­na­tion of its mus­cle-pre­serv­ing drugs with semaglu­tide, the ac­tive in­gre­di­ent in No­vo Nordisk’s Ozem­pic and We­govy.

The $105 bil­lion New York biotech said it an­tic­i­pates start­ing a Phase II study in mid-2024 that will test a range of dif­fer­ent dos­es and com­bi­na­tions of semaglu­tide, trevo­grum­ab (an an­ti-myo­statin an­ti­body) and gare­tos­mab (an an­ti-ac­tivin A an­ti­body). George Yan­copou­los, Re­gen­eron’s chief sci­en­tif­ic of­fi­cer, high­light­ed the loss of mus­cle as a con­cern­ing side ef­fect of obe­si­ty treat­ments like Ozem­pic and Eli Lil­ly’s Zep­bound.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.